Palatin Technologies | Home At Palatin, we drive our culture with science Our employees have unparalleled expertise related to the melanocortin system allowing them to develop potent, selective treatments for patients with unmet medical needs
Palatin Technologies | Pipeline Palatin is developing a truly novel class of drugs that selectively bind to melanocortin receptors (MCR), with both MCR1 and pan-agonists, to directly activate natural pathways that resolve disease inflammation in the eye
Palatin Technologies | About Us Robert has successfully managed several drug programs, including Palatin’s development of Vyleesi ® from phase 2 through NDA submission and FDA approval in 2019 as the only as-needed treatment for hypoactive sexual desire disorder (HSDD) Robert oversees all of Palatin’s drug development programs as well as leads clinical operations
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial . . . Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential For additional information regarding Palatin, please visit Palatin’s website at www Palatin com and follow Palatin on Twitter at @PalatinTech
Palatin Technologies Announces Pricing of up to $23 Million Public . . . CRANBURY, N J , May 7, 2025 PRNewswire — Palatin Technologies, Inc (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its public offering with
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients . . . Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential
Palatin Reports Positive Appetite Suppression Results From Phase 2 . . . Palatin continues to advance its next-generation MC4R agonists, including long-acting peptides and oral small molecules, targeting broad obesity indications—including monotherapy and combination regimens with incretin-based therapies, as well as rare and genetic obesity disorders such as hypothalamic obesity
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1 . . . Palatin is advancing the development of its next-generation MC4R long-acting peptide and oral small molecule compounds for the treatment of general obesity, weight loss management, acquired and congenital hypothalamic obesity, and potentially, rare orphan genetically caused MC4R pathway diseases